View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Irhythm Technologies Inc: 1 director

A director at Irhythm Technologies Inc sold 5,000 shares at 175.000USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

 PRESS RELEASE

AMALFI Randomized Clinical Trial Results Demonstrate Increased Atrial ...

AMALFI Randomized Clinical Trial Results Demonstrate Increased Atrial Fibrillation Diagnosis with Home-Based Long-Term Continuous ECG Monitoring Using iRhythm Technologies’ Zio LTCM Service Oxford University-led AMALFI clinical trial results presented at the European Society of Cardiology (ESC) Congress 2025 and published in the Journal of the American Medical Association (JAMA).AMALFI tested whether home-based, self-applied use of iRhythm’s Zio long-term continuous monitoring (LTCM) device and service could improve diagnosis of atrial fibrillation (AFib) in 5040 participants in the United ...

 PRESS RELEASE

iRhythm Technologies to Participate in Upcoming Investor Conferences

iRhythm Technologies to Participate in Upcoming Investor Conferences SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that its management team is scheduled to present at the following investor conferences. Wells Fargo 2025 Healthcare Conference on Wednesday, September 3, 2025, at 12:45 p.m. Eastern Time (9:45 a.m. Pacific Time)Morgan Stanley Global Healthcare Conference 2025 on Tuesday, September 9, 2025, at 2:35 p.m. Eastern Time (11:35 a...

 PRESS RELEASE

AVALON Real-World Evidence Builds on CAMELOT Study Reinforcing iRhythm...

AVALON Real-World Evidence Builds on CAMELOT Study Reinforcing iRhythm’s Zio LTCM Clinical Superiority In the largest real-world study of its kind with 428,707 patients, the Zio LTCM service outperformed other studied monitoring approaches in cardiac arrhythmia diagnostic yield, time to diagnosis, cardiovascular events, and total health care costs.Findings in a younger, commercially insured population build on data from the Medicare fee-for-service, population-based CAMELOT study, confirming the Zio LTCM service’s value across patient populations and payer segments. SAN FRANCISCO, Aug....

 PRESS RELEASE

iRhythm and Lucem Health Partner to Introduce Predictive AI Solution f...

iRhythm and Lucem Health Partner to Introduce Predictive AI Solution for Early Detection of Arrhythmias in Patient Populations with Comorbid Conditions Partnership aims to utilize predictive AI to help identify arrhythmias earlier in patient populations with an elevated risk for arrhythmias to enable timely care for millions who remain undiagnosedCommercial offering from this collaboration designed to support scalable population health and value-based care strategies SAN FRANCISCO, July 31, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a digital health leader focused on creating trusted solut...

 PRESS RELEASE

iRhythm Technologies Announces Second Quarter 2025 Financial Results

iRhythm Technologies Announces Second Quarter 2025 Financial Results SAN FRANCISCO, July 31, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended June 30, 2025. Second Quarter 2025 Financial Highlights Revenue of $186.7 million, a 26.1% increase compared to second quarter 2024Gross margin of 71.2%, a 130-basis point increase compared to second quarter 2024Unrestricted cash, cash equivalents, and marketable securit...

 PRESS RELEASE

iRhythm Technologies to Report Second Quarter 2025 Financial Results o...

iRhythm Technologies to Report Second Quarter 2025 Financial Results on July 31, 2025 SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the second quarter 2025 after the close of trading on Thursday, July 31, 2025. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the confere...

 PRESS RELEASE

iRhythm Technologies Announces Board Member Retirements and New Direct...

iRhythm Technologies Announces Board Member Retirements and New Director Appointments SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC) , a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the retirement of two long-serving board members, Mark Rubash and Ralph Snyderman, M.D., effective July 7, 2025. Concurrently, Karen McGinnis and Kevin O’Boyle have accepted appointments to the board of directors. Mark Rubash has served on the board since 2016, prior to the company’s initial public offerin...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

New Data Presented at ADA 2025 Highlights Burden and Risk Associations...

New Data Presented at ADA 2025 Highlights Burden and Risk Associations of Cardiac Arrhythmias in Patients with Type 2 Diabetes and Chronic Kidney Disease Retrospective real-world analyses of patients with type 2 diabetes—some of whom also had chronic kidney disease—demonstrate cardiac arrhythmias present frequent and early, often preceding major cardiovascular events (MACE) SAN FRANCISCO, June 23, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC) announced the results from two large-scale real-world studies presented at the American Diabetes Association’s 85th Scientific Sessions (ADA 2025). The ...

 PRESS RELEASE

iRhythm Technologies to Participate in Upcoming Investor Conferences

iRhythm Technologies to Participate in Upcoming Investor Conferences SAN FRANCISCO, May 21, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that its management team is scheduled to present at the following investor conferences. William Blair 45th Annual Growth Stock Conference on Wednesday, June 4, 2025, at 2:00 p.m. Central Time (12:00 p.m. Pacific Time)Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025, at 2:40 p.m. Eastern Time (...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

iRhythm Launches Zio® Long-Term Continuous Monitoring Service in Japan...

iRhythm Launches Zio® Long-Term Continuous Monitoring Service in Japan as the Zio® ECG Recording and Analysis System, Advancing AI-Powered Arrhythmia Detection iRhythm Zio® Long-Term Continuous Monitoring (LTCM) system — commercially introduced in Japan as the Zio® ECG Recording and Analysis System — brings AI-powered, continuous, uninterrupted ECG monitoring for up to 14 days to JapanLaunch is timely amid a growing demand for early, accurate detection of arrhythmias in Japan, the second largest ambulatory cardiac monitoring market in the world, where the prevalence is expected to rise alon...

 PRESS RELEASE

iRhythm Technologies Announces First Quarter 2025 Financial Results

iRhythm Technologies Announces First Quarter 2025 Financial Results SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2025. First Quarter 2025 Financial Highlights Revenue of $158.7 million, a 20.3% increase compared to first quarter 2024Gross margin of 68.8%, a 250-basis point increase compared to first quarter 2024Unrestricted cash, cash equivalents, and marketable securities of $520....

 PRESS RELEASE

iRhythm Technologies to Present at the Bank of America Securities 2025...

iRhythm Technologies to Present at the Bank of America Securities 2025 Health Care Conference SAN FRANCISCO, April 29, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced the company will be participating in the upcoming Bank of America Securities 2025 Health Care Conference. iRhythm’s management is scheduled to present on Tuesday, May 13, 2025, 3:40 p.m. Pacific Time/6:40 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presenta...

 PRESS RELEASE

iRhythm Presents New Real-World Data on Ambulatory Cardiac Monitoring ...

iRhythm Presents New Real-World Data on Ambulatory Cardiac Monitoring at HRS 2025 Reinforcing Clinical Superiority of Zio Long-Term Continuous Monitoring Findings in a younger, commercially insured population build on Medicare-based CAMELOT results, expanding the generalizability of Zio LTCM's clinical impact across patient groups.Latest data showed Zio LTCM was associated with higher diagnostic yield and lower likelihood of repeat testing and cardiovascular events compared to all other LTCM products. SAN FRANCISCO, April 28, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ:IRTC) announced res...

 PRESS RELEASE

iRhythm Technologies to Report First Quarter 2025 Financial Results on...

iRhythm Technologies to Report First Quarter 2025 Financial Results on May 1, 2025 SAN FRANCISCO, April 17, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the first quarter 2025 after the close of trading on Thursday, May 1, 2025. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the conference c...

 PRESS RELEASE

iRhythm Technologies Releases 2024 Corporate Sustainability Report Tha...

iRhythm Technologies Releases 2024 Corporate Sustainability Report That Demonstrates Ongoing Commitment to Culture of Quality and Sustainability Report highlights progress against key sustainability initiatives that reflect iRhythm’s commitment to delivering better data, better insights, and better health for all SAN FRANCISCO, April 16, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced that it has published its , highlighting the company’s efforts to build a su...

 PRESS RELEASE

iRhythm Unveils New Real-World Data at ACC.25 Demonstrating the Benefi...

iRhythm Unveils New Real-World Data at ACC.25 Demonstrating the Benefits of Zio® Long-Term Continuous Monitoring for Arrhythmia Detection Two large studies of over one million patients reveal that short-term Holter-duration monitoring frequently misses actionable arrhythmias and that patient-reported symptoms are an unreliable predictor of arrhythmic events SAN FRANCISCO, March 31, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ:IRTC) today announced results from two large real-world retrospective analyses presented at the American College of Cardiology (ACC) 2025 Scientific Sessions in Chicago, IL...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch